Rapamycin and Alzheimer's disease: Time for a clinical trial?

Sci Transl Med. 2019 Jan 23;11(476):eaar4289. doi: 10.1126/scitranslmed.aar4289.


The drug rapamycin has beneficial effects in a number of animal models of neurodegeneration and aging including mouse models of Alzheimer's disease. Despite its compelling preclinical record, no clinical trials have tested rapamycin or other mTOR inhibitors in patients with Alzheimer's disease. We argue that such clinical trials should be undertaken.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Aging / pathology
  • Alzheimer Disease / drug therapy*
  • Animals
  • Clinical Trials as Topic*
  • Humans
  • Sirolimus / therapeutic use*
  • TOR Serine-Threonine Kinases / metabolism
  • Treatment Failure


  • TOR Serine-Threonine Kinases
  • Sirolimus